We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Analgesic Treatment Mediated by Arcoxia (0663-093)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00380523
First Posted: September 26, 2006
Last Update Posted: March 17, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
September 22, 2006
September 26, 2006
March 17, 2015
April 2005
May 2005   (Final data collection date for primary outcome measure)
Evaluate pain using the verbal analog scale (evaluate pain before starting treatment and then evaluate pain every day after had taken arcoxia up to three days)
Same as current
Complete list of historical versions of study NCT00380523 on ClinicalTrials.gov Archive Site
  • Patient satisfaction with the drug therapy using PGART scale
  • Patient satisfaction was obtained at the end of treatment(on third day)
Same as current
Not Provided
Not Provided
 
Analgesic Treatment Mediated by Arcoxia (0663-093)
Analgesic Treatment Mediated by Arcoxia
Allow physicians to test the efficacy of arcoxia in patients with acute pain.
Not Provided
Interventional
Phase 4
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Pain
Drug: MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
237
May 2005
May 2005   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of acute pain susceptible of pharmacological treatment
  • Greater than 18 years of age
  • Voluntary acceptance to participate in the study and signature of the informed consent form

Exclusion Criteria:

  • Allergy to etoricoxib or any of its components
  • Less than 18 years old
  • Patient is taking anticoagulants
  • Patient that already has taken any drug as analgesic
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00380523
0663-093
2006_034
Not Provided
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
March 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP